Citi analyst Joanne Wuensch maintained a Buy rating on Johnson & Johnson yesterday and set a price target of $185.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Joanne Wuensch’s rating is based on Johnson & Johnson’s strong financial performance and strategic positioning. The company reported impressive revenue growth in the second quarter of 2025, surpassing market expectations. This was driven by robust performance in its Innovative Medicine and MedTech segments, with significant contributions from Cardiovascular and Vision Care. Despite a slight decline in operating margins, the company managed to exceed earnings per share forecasts, showcasing its operational efficiency.
Moreover, Johnson & Johnson’s management has raised its sales and earnings guidance for the year, indicating confidence in its future prospects. The company has also effectively managed policy-related challenges, such as tariff headwinds, by reinvesting savings into the business. Additionally, the MedTech segment showed resilience with notable growth in specific areas, further supporting the positive outlook. These factors collectively contribute to the Buy rating, reflecting optimism about the company’s ability to maintain its growth trajectory.
Wuensch covers the Healthcare sector, focusing on stocks such as Medtronic, Abbott Laboratories, and Dexcom. According to TipRanks, Wuensch has an average return of 6.4% and a 61.57% success rate on recommended stocks.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $185.00 price target.